2001

Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging and therapeutic agent of human cancer

Minh-Thu Nguyen Hang
University of Wollongong

UNIVERSITY OF WOLLONGONG
COPYRIGHT WARNING

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author.

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Recommended Citation

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au
NOTE
This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

UNIVERSITY OF WOLLONGONG

COPYRIGHT WARNING

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.
ASSESSMENT OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2 (PAI-2) AS AN IMAGING AND THERAPEUTIC AGENT OF HUMAN CANCER

A thesis submitted in fulfilment of the requirements for the award of the degree

PhD

from

UNIVERSITY OF WOLLONGONG

by

MINH-THU NGUYEN HANG, B.Sc.(Hons)

DEPARTMENT OF BIOLOGICAL SCIENCES
2001
STATEMENT OF ORIGINALITY

I, Minh-Thu N. Hang, declare that this thesis contains no material which has been accepted for the award of any degree or diploma in any University, and to the best of my knowledge contains no material which has been previously published or written by another person except where due reference is made in the text of this thesis.

Minh-Thu N. Hang
ACKNOWLEDGEMENTS

My gratitude goes out to quite a lot of people who have helped and supported me throughout my PhD. Thank-you to my supervisors Clive Bunn and Mark Baker for giving me an interesting project to work on and especially Clive, for sharing with me his enthusiasm for science. Thank-you to my two advisors Marie Ranson and Xiao-Ming Liang for the guidance and technical assistance they provided. A special thanks to Marie for all the encouragement and positive attitude when experiments were not working. Thank-you to my friends from the Department of Biological Sciences and students from lab112 for their friendship and humour. Thank-you to Professor Rob Whelan, for his support and words of advice throughout.

Special thanks to the people at Biotech Australia for all the PAI-2 preparations and numerous reagents and supplementing my PhD scholarship. Thank-you to Southern Pathology and the people in the Department of Histology at North Wollongong Hospital for histological sectioning and staining.

Most importantly, the achievement of my PhD is due to the love and support from my family, Cha (dad), Me (mom), Quynh-Thu, Anh-Thu, and my husband, Michael. I am deeply greatful to my family for always being there for me and believing in me. Thank-you to Cha and Me, through the sacrifices they made to provide me a good education. Thank-you Michael for being so patient with all the late nights in the lab, the cranky moods and the instant noodle dinners and for proof reading this thesis.
ABSTRACT

The plasminogen activation cascade is an important proteolytic pathway involved in the growth and spread of cancer. Potentially, an inhibitor of plasminogen activation could make an excellent cancer imaging agent or cancer treatment. The aim of this thesis was to assess whether plasminogen activator inhibitor 2 (PAI-2) can image or treat colorectal cancer. The first part of this thesis examined the ability of PAI-2 to bind specifically to the human colorectal cancer cell line HCT116. These experiments involved confirmation of u-PA expression by HCT116 cells and cell binding studies with $^{125}$I-PAI-2. The second part was examining the biodistribution and kinetics of $^{125}$I-PAI-2 in nude mice bearing tumour xenografts derived from HCT116 cells. The final part involved examining the effect PAI-2 treatment had on mice bearing HCT116 tumour xenografts.

PAI-2 was found to bind specifically to u-PA on HCT116 cells. There appeared to be a high turnover rate of bound PAI-2 because it was difficult to detect $^{125}$I-PAI-2/u-PA complexes by autoradiography. $^{125}$I-PAI-2 had a biphasic distribution in the bloodstream of control mice (distribution phase ($T_{1/2a}$) 12.5min, elimination phase ($T_{1/2b}$) 342min) and mice bearing tumour xenografts ($T_{1/2a}$ 1.4min, $T_{1/2b}$ 29min). Approximately 1% of $^{125}$I-PAI-2 localised to the tumour xenograft after a single intravenous injection. However, more $^{125}$I-PAI-2 could be localised to the tumour by multiple intravenous injections. From three separate therapy experiments with PAI-2, there did not appear to be any effect on relatively large tumours. However, in one
experiment PAI-2 injections did cause two 1mm tumours to disappear. In conclusion, PAI-2 does bind to u-PA on HCT116 cells \textit{in vitro}. \textit{In vivo}, injected PAI-2 appeared unsuitable for the imaging of tumours or metastasis. However preliminary data from this thesis suggest that PAI-2 may have therapeutic potential against smaller tumours.
LIST OF TABLES AND FIGURES

CHAPTER 1

Figure 1. A simplified schematic diagram representing the steps of cancer metastasis.

Figure 2. A simplified schematic diagram of the components of the plasminogen/plasmin system.

Figure 3. Modified schematic representation of u-PA and t-PA structure and the binding of u-PA to it’s specific receptor, u-PAR (Andreasen et al., 1994).

Table I. Properties of PAI-1, PAI-2, PAI-3 and PN-1.

CHAPTER 2

Figure 1. Flow cytometric analysis on the expression of u-PA and u-PAR on the cell surface of HCT116 and LIM1215 cells.

Figure 2. Cell surface expression of u-PA and u-PAR on HCT116 and LIM1215 cells.

Figure 3. The effect of plasminogen treatment on cell surface expression of u-PA and u-PAR by HCT116 and LIM1215 cells.

Figure 4. The effect of human recombinant PAI-2 and u-PA inhibitory monoclonal antibody on u-PA activity of HCT116 cell lysates.

Figure 5. Characterisation of $^{125}$I-PAI-2.

Figure 6. $^{125}$I-PAI-2 binding to varying concentrations of u-PA analysed by autoradiography.

Figure 7. Optimisation of plasminogen concentration used in the $^{125}$I-PAI-2 cell binding studies.

Figure 8. Time course for $^{125}$I-PAI-2 binding to HCT116 cells at 4°C.

Figure 9. $^{125}$I-PAI-2 binding to HCT116 cells.
Figure 10. The specific binding of $^{125}$I-PAI-2 to plasminogen treated (graph A) and untreated (graph B) HCT116 cells.

Figure 11. Concentration courses for the inhibitors of u-PA activity.

Figure 12. $^{125}$I-PAI-2 binding to active u-PA on HCT116 cells.

Figure 13. $^{125}$I-PAI-2 binding to HCT116 cells for various times analysed by autoradiography.

Figure 14. $^{125}$I-PAI-2 binding to HCT116 cells after being left for 6h at 4°C analysed by autoradiography.

Figure 15. The effects of plasminogen treatment on $^{125}$I-PAI-2 cross-linked to HCT116 cells.

Figure 16. Processing of $^{125}$I-PAI-2 by HCT116 cells at 37°C.

CHAPTER 3

Figure 1. Athymic Swiss outbred Nu/Nu mice.

Table I Outline of the experiments analysing the kinetics and biodistribution of $^{125}$I-hPAI-2 in control and tumour bearing mice.

Table II Experimental outline of the biodistribution studies of $^{125}$I-mPAI-2.

Table III Imaging studies experimental outline.

Figure 2. Characterisation of $^{125}$I-mouse PAI-2 (mPAI-2).

Figure 3. Biphasic clearance of $^{125}$I-hPAI-2 from plasma of nude mice with or without xenografts of the human colon cancer cell line, HCT116.

Figure 4. Analysis of plasma from control (A) and tumour-bearing mice (B) after intravenous injection with $^{125}$I-hPAI-2.

Figure 5. Characterisation of the activity of intravenously injected $^{125}$I-hPAI-2 in plasma from tumour-bearing mice.

Figure 6. The clearance and characterisation of $^{125}$I-hPAI-2 in mouse urine.
Figure 7. The uptake and clearance of $^{125}$I-hPAI-2 by organs and tissues from control mice.

Figure 8. The uptake and clearance of $^{125}$I-hPAI-2 by organs and tissues from tumour-bearing mice.

Figure 9. Tissue distribution of $^{125}$I-hPAI-2 at 5min (A), 30min (B) and 60min (C) post-intravenous injection in control and tumour-bearing mice.

Figure 10. Relationship between tumour mass and the amount of radioactivity accumulated in the tumour.

Figure 11. $^{125}$I-mPAI-2 in plasma of control and tumour-bearing mice.

Figure 12. Tissue distribution of $^{125}$I-mPAI-2 at 5min (graph A), 30min (graph B) and 60min (graph C) post-intravenous injection in control and tumour-bearing mice.

Figure 13. Increased accumulation of radioactivity in the tumors after multiple injections of $^{125}$I-hPAI-2.

Figure 14 PAI-2 antigen in liver, kidney and tumour xenograft homogenates.

Figure 15 Immunoprecipitation of hPAI-2 from liver and tumour xenograft homogenates.

Figure 16 u-PA activity measured in tumour xenograft and kidney homogenates.

Figure 17 Radioactivity in organs and tissues of tumour-bearing mice at 5min and 60min after i.v. injections of $^{125}$I-hPAI-2.

Figure 18 Graphical representation of the distribution of radioactivity (intensity/pixel) in organs and tissues of tumour-bearing mice, 5min (A) and 60min (B) after i.v injection of $^{125}$I-hPAI-2.

CHAPTER 4

Table I. Experimental outline of therapy experiment 1.

Table II. Experimental outline of therapy experiment 2.
Figure 1. A photograph of a nude mice, with a tumour xenograft of HCT116 cells.

Table III. Experimental outline of therapy experiment 3.

Figure 2. Characterisation of human recombinant PAI-2 for use in therapy experiments.

Table IV. The macroscopic observations of the effect PAI-2 treatment had on the tumour xenograft at the end of therapy experiment 1.

Figure 3. Photographs of a tumour mass A), lung metastasis B) and an enlarged lymph node C).

Figure 4. H&E staining of pulmonary metastasis in nude mice with subcutaneous tumour xenograft from therapy experiment 1.

Figure 5. The effect of PAI-2 injection on the weight of mice from therapy experiment 1.

Figure 6. The effect of PAI-2 injection on the diameter of tumour xenografts from therapy experiment 1.

Figure 7. The effect of PAI-2 injection on the mass of tumour xenografts from therapy experiment 1.

Figure 8. The relationship between tumour mass and tumour diameter in therapy experiment 1.

Table V. The macroscopic observations of the effect PAI-2 treatment had on the tumour xenograft at the end of therapy experiment 2.

Figure 9. The effect of PAI-2 treatment on the weight of the mice from therapy experiment 2.

Figure 10. The effect of PAI-2 injection on the diameter of tumour xenografts from therapy experiment 2.

Figure 11. The effect of PAI-2 injection on the mass of tumour xenografts from therapy experiment 2.

Figure 12. The relationship between tumour mass and tumour diameter in therapy experiment 2.
Table VI. The macroscopic observations of the effect PAI-2 treatment had on the tumour xenograft at the end of therapy experiment 3.

Figure 13. The effect of PAI-2 injection on the weight of the mice from therapy experiment 3.

Figure 14. The effect of PAI-2 injection on the diameter of tumour xenografts from therapy experiment 3.

Figure 15. The effect of PAI-2 injection on the mass of the tumour xenografts from therapy experiment 3.

Figure 16. The effects of PAI-2 treatment on tumour diameter and growth rate.

Figure 17. The relationship between tumour diameter and tumour mass in therapy experiment 3.

Figure 18. PAI-2 antigen in plasma samples and tissue homogenates from the third therapy experiment.

Figure 19. u-PA activity of tissue homogenates from therapy experiment 3.

Figure 20. Zymographs of homogenates of tumour xenograft and liver from therapy experiment 3.

Figure 21. H&E staining of cultured HCT116 cells and tumours derived from HCT116 cells.

Figure 22. H&E staining of pulmonary metastasis in nude mice with subcutaneous tumour xenograft.
### ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>#387</td>
<td>t-PA monoclonal antibody</td>
</tr>
<tr>
<td>#394</td>
<td>u-PA monoclonal antibody</td>
</tr>
<tr>
<td>#3750</td>
<td>PAI-2 monoclonal antibody</td>
</tr>
<tr>
<td>#3936</td>
<td>u-PAR monoclonal antibody</td>
</tr>
<tr>
<td>API</td>
<td>Activator protein 1</td>
</tr>
<tr>
<td>ATTC</td>
<td>American Tissue Type Collection</td>
</tr>
<tr>
<td>B428</td>
<td>4-iodobenzo[b]thiopene-2-carboxamidine, a synthetic u-PA inhibitor</td>
</tr>
<tr>
<td>bFGF</td>
<td>Basic fibroblast growth factor</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CEA</td>
<td>Carcinoembryonic antigen</td>
</tr>
<tr>
<td>DNP-9</td>
<td>IgG1 isotype control antibody</td>
</tr>
<tr>
<td>DTNB</td>
<td>5,5'-dithiobis (2-nitrobenzoic acid)</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>EGR-CMK</td>
<td>Glu-Gly-Arg chloromethyl ketone</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme linked immunosorbent assay</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal bovine serum</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>G155-78</td>
<td>IgG2a isotype control antibody</td>
</tr>
<tr>
<td>GFD</td>
<td>Growth factor domain</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte-macrophage colony stimulating factor</td>
</tr>
<tr>
<td>gp330</td>
<td>Glycoprotein 330</td>
</tr>
<tr>
<td>GPI</td>
<td>Glycosylphosphatidylinositol</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Hematoxylin &amp; Eosin</td>
</tr>
<tr>
<td>hPAI-2</td>
<td>Human plasminogen activator inhibitor type 2</td>
</tr>
<tr>
<td>HUVEC</td>
<td>Human umbilical vein endothelial cells</td>
</tr>
<tr>
<td>i.p.</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>i.v.</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IL-1</td>
<td>Interleukin-1</td>
</tr>
<tr>
<td>IL-2</td>
<td>Interleukin-2</td>
</tr>
<tr>
<td>IUGR</td>
<td>Intra-uterine growth retardation</td>
</tr>
<tr>
<td>Kd</td>
<td>Dissociation constant</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>LRP</td>
<td>Low density lipoprotein receptor-related protein</td>
</tr>
<tr>
<td>M-CSF</td>
<td>Macrophage colony stimulating factor</td>
</tr>
<tr>
<td>MMP-2</td>
<td>Matrix metalloproteinase 2</td>
</tr>
<tr>
<td>mPAI-2</td>
<td>Mouse plasminogen activator inhibitor type 2</td>
</tr>
<tr>
<td>Mr</td>
<td>Molecular weight</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>OPD</td>
<td>o-Phenyldiamine</td>
</tr>
<tr>
<td>PA</td>
<td>Plasminogen activator</td>
</tr>
<tr>
<td>PAI</td>
<td>Plasminogen activator inhibitor</td>
</tr>
<tr>
<td>PAI-1</td>
<td>Plasminogen activator inhibitor type 1</td>
</tr>
<tr>
<td>PAI-2</td>
<td>Plasminogen activator inhibitor type 2</td>
</tr>
<tr>
<td>PAI-3</td>
<td>Plasminogen activator inhibitor type 3</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PEG</td>
<td>Polyethylene glycol</td>
</tr>
<tr>
<td>PGE₂</td>
<td>Prostaglandin E₂</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium iodide</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PLD</td>
<td>Phospholipase D</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol myristate acetate</td>
</tr>
<tr>
<td>PMSF</td>
<td>Phenylmethylsulfoxide fluoride</td>
</tr>
<tr>
<td>PN-1</td>
<td>Protease nexin 1</td>
</tr>
<tr>
<td>r²</td>
<td>Correlation coefficient</td>
</tr>
<tr>
<td>RAP</td>
<td>Receptor associated protein</td>
</tr>
<tr>
<td>RIA</td>
<td>Radioimmunoassay</td>
</tr>
<tr>
<td>RIGS</td>
<td>Radioimmunoguided surgery</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>s.c.</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>sc-tPA</td>
<td>Single chain tissue type plasminogen activator</td>
</tr>
<tr>
<td>sc-uPA/pro-u-PA</td>
<td>Single chain urokinase type plasminogen activator</td>
</tr>
<tr>
<td>SCID</td>
<td>Severe combined immunodeficient</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulphate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SERPIN</td>
<td>Serine protease inhibitor</td>
</tr>
<tr>
<td>SLE</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>TAG</td>
<td>Tumour associated glycoprotein</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris buffered saline</td>
</tr>
<tr>
<td>tc-tPA</td>
<td>Twin chain tissue type plasminogen activator</td>
</tr>
<tr>
<td>tc-uPA</td>
<td>Twin chain urokinase type plasminogen activator</td>
</tr>
<tr>
<td>TCA</td>
<td>Trichloroacetic acid</td>
</tr>
<tr>
<td>TGF-α</td>
<td>Transforming growth factor α</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>Transforming growth factor β1</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor necrosis factor alpha</td>
</tr>
<tr>
<td>TNP</td>
<td>Trinitrophenol</td>
</tr>
<tr>
<td>t-PA</td>
<td>Tissue type plasminogen activator</td>
</tr>
<tr>
<td>TSP-1</td>
<td>Thrombospondin 1</td>
</tr>
<tr>
<td>u-PA</td>
<td>Urokinase type plasminogen activator</td>
</tr>
<tr>
<td>u-PAR</td>
<td>Urokinase type plasminogen activator receptor</td>
</tr>
<tr>
<td>UV</td>
<td>ultra-violet</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
</tbody>
</table>
VLDL Very low density lipoprotein receptor
ZLS Z-lysine thibenzyl ester
TABLE OF CONTENTS

STATEMENT OF ORIGINALITY ............................................i
ACKNOWLEDGMENTS .......................................................ii
ABSTRACT .................................................................iii
LIST OF FIGURES AND TABLES ..........................................v
ABBREVIATIONS ..........................................................x
TABLE OF CONTENTS ...................................................xiii

1. THE PLASMINOGEN ACTIVATION CASCADE, CANCER IMAGING 
AND THERAPY ......................................................................1

1.1 INTRODUCTION .......................................................... 1
1.2 CANCER INVASION AND METASTASIS ............................ 2
  1.2.1 The Metastatic Process ............................................. 2
  1.2.2 Cellular Movement .................................................. 3
  1.2.3 Routes of Cancer Spread .......................................... 4
1.2.4 Involvement of proteolytic enzymes in cancer metastasis ....... 4
1.3 PLASMINOGEN/PLASMIN SYSTEM ................................... 5
  1.3.1 Plasminogen and Plasmin ......................................... 6
    1.3.1.1 Synthesis ...................................................... 6
    1.3.1.2 Proteolytic Activity of Plasmin ............................ 6
    1.3.1.3 Inhibitors of Plasmin .................................... 8
  1.3.2 Plasminogen Activators (PAs) ................................... 9
    1.3.2.1 Tissue-type plasminogen activator (t-PA) ............... 10
    1.3.2.2 Urokinase-type plasminogen activator .................. 14
      1.3.2.2.1 Synthesis ............................................... 14
      1.3.2.2.2 Pro-u-PA ............................................... 15
      1.3.2.2.3 Regulation of u-PA ................................... 17
        1.3.2.2.3.1 Growth Factors ................................. 17
        1.3.2.2.3.2 Cytokines ....................................... 19
        1.3.2.2.3.3 Hormones ..................................... 20
        1.3.2.2.3.4 Others ......................................... 20
      1.3.2.2.4 Urokinase-type Plasminogen Activator Receptor (u-PAR) ... 22
      1.3.2.2.5 u-PA and cancer ................................... 22
      1.3.2.2.6 Localisation of u-PA in cancerous tissues and cells .... 25
      1.3.2.2.7 The interaction of u-PA with u-PAR in cancer metastasis .. 26
1.3.3 Plasminogen Activator Inhibitors .............................................. 28
  1.3.3.1 PAI-2 .............................................................................. 29
    1.3.3.1.1 Biokinetics ................................................................. 29
    1.3.3.1.2 Localisation ............................................................... 30
    1.3.3.1.3 Regulation .................................................................. 31
      1.3.3.1.3.1 Growth factors ...................................................... 31
      1.3.3.1.3.2 Cytokines .............................................................. 32
      1.3.3.1.3.3 Hormones ............................................................. 33
      1.3.3.1.3.4 Others ................................................................. 33
    1.3.3.1.4 Interaction between PAI-2 and u-PA ............................ 35
    1.3.3.1.5 Cellular processing of PAI-2 ........................................ 36
      1.3.3.1.6 Functions/roles of PAI-2 ........................................... 38
        1.3.3.1.6.1 Keratinocyte differentiation ................................. 38
        1.3.3.1.6.2 Inflammation, wound healing and apoptosis ......... 41
        1.3.3.1.6.3 Pregnancy .......................................................... 43
        1.3.3.1.6.4 Pre-eclampsia ...................................................... 49
        1.3.3.1.6.5 Intrauterine fetal growth retardation (IUGR) ......... 50
        1.3.3.1.6.6 Other disease states ........................................... 50
        1.3.3.1.6.7 PAI-2 and cancer ............................................... 51
  1.4 ANIMAL MODELS IN CANCER RESEARCH ................................. 55
    1.4.1 The use of nude mouse models in cancer research ............. 56
      1.4.1.1 Transplantation of human tumours into nude mice ......... 58
        1.4.1.1.1 Subcutaneous inoculation ...................................... 59
        1.4.1.1.2 Intravenous injection ............................................ 60
        1.4.1.1.3 Orthotopic transplantation .................................... 60
  1.5 IMAGING AGENTS FOR HUMAN CANCERS ................................. 61
    1.5.1 Imaging agents .............................................................. 62
  1.6 THERAPEUTIC STRATEGIES FOR THE TREATMENT OF HUMAN
    CANCERS .............................................................................. 64
  1.7 FOCUS OF THE PROJECT .......................................................... 69

2. IN VITRO STUDIES OF RECOMBINANT HUMAN PAI-2 USING THE
  HUMAN COLORECTAL CANCER CELL LINE HCT116 ........................... 70

2.1 INTRODUCTION .......................................................................... 70
2.2 MATERIALS AND METHODS ...................................................... 73
  2.2.1 Reagents ............................................................................ 73
  2.2.2 Cell culture ......................................................................... 75
  2.2.3 Flow cytometric analysis of cell surface u-PA and u-PAR on viable
    HCT116 and LIM1215 cells ...................................................... 76
      2.2.3.1 Detection of cell surface u-PA and u-PAR ....................... 76
      2.2.3.2 Effects of plasminogen treatment on cell surface u-PA and u-PAR
        levels ................................................................. 78
      2.2.3.3 Data analysis ........................................................... 79
  2.2.4 u-PA activity of HCT116 ..................................................... 79
2.2.4.1 Lysis of HCT116 cells ................................................................. 79
2.2.4.2 Measurement of u-PA activity of HCT116........................................... 80
2.2.5 Iodination of recombinant human PAI-2 and characterisation of $^{125}$I-PAI-2 ................................................................. 81
2.2.5.1 Iodination ................................................................................... 81
2.2.5.2 Characterisation of $^{125}$I-PAI-2 ....................................................... 82
2.2.6 $^{125}$I-PAI-2 binding assay ................................................................. 84
2.2.6.1 Optimisation of plasminogen concentration ........................................ 84
2.2.6.2 Time course of $^{125}$I-PAI-2 binding to HCT116 cells ......................... 85
2.2.6.3 Optimisation of $^{125}$I-PAI-2 concentration ........................................ 85
2.2.6.4 Scatchard analysis of $^{125}$I-PAI-2 binding to HCT116 cells ................. 86
2.2.6.5 Optimisation of inhibitors of u-PA activity ........................................ 87
2.2.6.6 Specific inhibition of $^{125}$I-PAI-2 binding to HCT116 cells ................. 88
2.2.7 SDS-PAGE analysis of $^{125}$I-PAI-2 binding to HCT116 cells ................. 88
2.2.8 Cross-linking of $^{125}$I-PAI-2 to HCT116 ............................................. 90
2.2.8.1 Purification of plasma membrane from HCT116 cells ....................... 90
2.2.8.2 Cross-linking with DSS .................................................................. 91
2.2.9 $^{125}$I-PAI-2 binding and degradation at 37 °C .................................... 92
2.2.10 Statistical analysis of data .................................................................. 94
2.3 RESULTS .......................................................................................... 94
2.3.1 Cell-surface expression of u-PA and u-PAR on HCT116 and LIM1215 cells ........................................................................... 94
2.3.2 u-PA activity of HCT116................................................................... 95
2.3.3 Active $^{125}$I-PAI-2 ......................................................................... 96
2.3.4 Optimisation of plasminogen concentration for $^{125}$I-PAI-2 binding to HCT116 cells ................................................................. 99
2.3.5 Time course of $^{125}$I-PAI-2 binding to HCT116 cells at 4°C ................... 100
2.3.6 The effect of increasing concentrations of $^{125}$I-PAI-2 binding to HCT116 cells ........................................................................... 102
2.3.7 Scatchard analysis ............................................................................. 103
2.3.8 Optimal concentration of u-PA inhibitors ............................................ 104
2.3.9 $^{125}$I-PAI-2 binds specifically to active u-PA on HCT116 cells ............... 105
2.3.10 Analysis of $^{125}$I-PAI-2 binding to HCT116 cells by SDS-PAGE ........ 106
2.3.11 Crosslinking of $^{125}$I-PAI-2 to HCT116 .............................................. 108
2.3.12 Processing of $^{125}$I-PAI-2 at 37 °C .................................................. 110
2.4 DISCUSSION .................................................................................... 110

3. DETERMINATION OF THE CLEARANCE AND BIODISTRIBUTION OF IODINATED PAI-2 ($^{125}$I-PAI-2) USING A SUBCUTANEOUS XENOGRAFT NUDE MOUSE MODEL OF THE HUMAN COLORECTAL CANCER CELL LINE HCT116 ................................................................. 119

3.1 INTRODUCTION ................................................................................. 119
3.2 MATERIALS AND METHODS ............................................................ 122
3.2.1 Reagents ....................................................................................... 122
4. ASSESSMENT OF RECOMBINANT HUMAN PAI-2 AS A THERAPY FOR HUMAN COLORECTAL CANCER

4.1 INTRODUCTION

4.2 MATERIALS AND METHODS

4.2.1 Materials

4.2.2 Cell culture

4.2.3 Animals

4.2.4 Preparation of cells for injection

4.2.5 Xenografts of human colon cancer in nude mice

4.2.6 Characterisation of PAI-2

4.2.7 Therapy experiment 1

4.2.8 Therapy experiment 2

4.2.9 Therapy experiment 3